Document is current
Any future updates will be listed below
-
Authors
Citarella, Fabrizio
Takada, Kazuki
Cascetta, Priscilla
Crucitti, Pierfilippo
Petti, Roberta
Vincenzi, Bruno
Tonini, Giuseppe
Venanzi, Francesco M.
Bulotta, Alessandra
Oresti, Sara
Greco, Carlo
Ramella, Sara
Crinò, Lucio
Delmonte, Angelo
Ferrara, Roberto
Di Maio, Massimo
Gurrieri, Fiorella
Cortellini, Alessio https://orcid.org/0000-0002-1209-5735
- License Information
-
More Information
Article History
Received: 2 July 2024
Accepted: 24 July 2024
First Online: 31 July 2024
Declarations
:
: All the study procedures will follow the precepts of Good Clinical Practice and the declaration of Helsinki. The study was approved by the local ethical committees on human experimentation (Comitato Etico Territoriale Lazio AREA 2, registro sperimentazioni 27.23 CET 2 CBM, 12 Oct 2023).
: Alessio Cortellini declares speaker’s fees from MSD, AstraZeneca, Pierre-Fabre, EISAI, Sanofi/REGENERON, and Roche (outside of the present work) and advisory board roles/grant for consultancies from MSD, BMS, AstraZeneca, Roche, OncoC4, IQVIA, Pierre-Fabre, EISAI, REGENERON, Sanofi/REGENERON, Ardelis Health, AlphaSight, Access Infinity (outside of the present work). He also declares travel support from MSD and Roche. Sara Ramella declares advisory board roles and grant consultancies from Astra Zeneca, MSD (Merk) and Roche (outside of the present work). All other authors declare no conflicts of interest associated with the present study.
